LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Search

Pliant Therapeutics Inc

Open

1.21 1.68

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.21

Max

1.25

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.5M

-20M

EPS

-0.32

Angestellte

49

EBITDA

6.8M

-22M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+120.66% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.2M

73M

Vorheriger Eröffnungskurs

-0.47

Vorheriger Schlusskurs

1.21

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Mai 2026, 08:24 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. Mai 2026, 21:22 UTC

Ergebnisse

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. Mai 2026, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

25. Mai 2026, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

25. Mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. Mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. Mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. Mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. Mai 2026, 12:56 UTC

Market Talk
Ergebnisse

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. Mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. Mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. Mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. Mai 2026, 12:10 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Delivery Hero's Assets Look Strategic -- Market Talk

25. Mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. Mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. Mai 2026, 10:05 UTC

Ergebnisse

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. Mai 2026, 10:04 UTC

Ergebnisse

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. Mai 2026, 10:03 UTC

Ergebnisse

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. Mai 2026, 10:02 UTC

Ergebnisse

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. Mai 2026, 10:01 UTC

Ergebnisse

Tenaga Nasional 1Q Net Up 3.7% on Year

25. Mai 2026, 10:00 UTC

Ergebnisse

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q EPS MYR0.1883

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q Rev MYR17.1B

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q Net MYR1.1B

25. Mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. Mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. Mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. Mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

120.66% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD  120.66%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

1

Buy

4

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat